From USFDA
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Testosterone Cypionate Injection 100mg/ml and 200mg/ml from the United States Food and Drug Administration (US FDA).Cipla's Testosterone Cypionate Injection 100mg/ml and 200mg/ml is AO-rated generic therapeutic equivalent version of Pharmacia and Upjohn's Depo-Testosterone. It is indicated for replacement therapy in males in conditions associated with symptoms of deficiency or absence of endogenous testosterone.
According to IQVIA (IMS Health), Depo-Testosterone and its generic equivalents had US sales of approximately $191M for the 12-month period ending April 2018.
The product is available for shipping immediately.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)